Claims for Patent: 7,704,984

Summary for Patent: 7,704,984

Title:	Extended estrogen dosing contraceptive regimen
Abstract:	A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22 to about 26 days; (b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 2 to about 3 days and an optional third composition that is a placebo provided that (i) if estrogen administration is continuous then the first composition is administered for 25 to 26 days, the second composition is administered for 2 to 3 days and no third composition is administered and (ii) if estrogen administration is not continuous then the first composition is administered for 22 to 24 days, the second composition is administered for 2 to 3 days and the third composition is administered for 1 to 4 days. The total cycle length is 28 days, with the first composition administered on day 1 of the menstrual cycle, defined as the first day of menstrual bleeding, or on the first Sunday after the first day of the menstrual cycle.
Inventor(s):	Boissonneault; Roger M. (Long Valley, NJ)
Assignee:	Warner Chilcott Company, LLC (Fajardo, PR)
Application Number:	11/112,290
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,704,984
Patent Claims:	1. A method of contraception comprising the steps of sequentially administering to a female of child-bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate wherein the progestin is selected from norethindrone acetate or norethindrone and 5 to 15 mcg of ethinyl estradiol for 24 days; (b) a second composition containing 5 to 15 mcg of ethinyl estradiol and substantially free of a progestin for 2 days; and (c) a third composition that is a placebo, wherein the sequential administration of the first composition, the second composition and the third composition, is performed on a daily basis over a 28 day cycle. 2. The method according to claim 1, wherein the sequential administration is repeated beginning the day after completion of the 28 day cycle. 3. The method according to claim 1, wherein the progestin in the first composition is norethindrone acetate. 4. The method according to claim 3, wherein the amount of norethindrone acetate in the first composition is about 1 mg. 5. The method according to claim 1, wherein the placebo contains about 75 mg of ferrous fumarate. 6. The method according to claim 4, wherein the amount of ethinyl estradiol in the first and second composition is the same. 7. A method of contraception comprising the steps of sequentially administering to a female of child bearing age: (a) a first composition containing about 0.3 to about 1.5 mg norethindrone acetate and 5 to 15 mcg ethinyl estradiol for 24 days; (b) a second composition containing 5 to 15 mcg of ethinyl estradiol and substantially free of a progestin for 2 days; (c) a third composition that is a placebo for 2 days, wherein the sequential administration of the first composition, the second composition and the third composition is performed on a daily basis over a 28 day cycle. 8. The method according to claim 7, wherein the first composition contains about 1 mg of norethindrone acetate. 9. The method according to claim 7, wherein the amount of ethinyl estradiol in the first and second composition is the same.